The Contract Development and Manufacturing Organization (CDMO) sector involves companies that provide services to help other businesses develop and manufacture pharmaceutical products. They handle tasks like drug development, production, and packaging for various clients.
The global CDMO market is projected to reach US$ 300 billion by 2028 from US$ 214 billion, which translates to an increase of 42 percent. India’s share in the global CDMO market is anticipated to grow 75 percent from US$ 8 billion in 2024 to US$14 billion in 2028.
According to Ace Investor, Madhu Kela, the CDMO industry is positioned for significant growth, with an estimated US$ 6 billion opportunity over the next three years.
1. Akums Drugs & Pharmaceuticals Ltd
The shares of Akums Drugs & Pharmaceuticals Ltd, with a total market capitalization of Rs 7,642.27 Crore on Thursday, were trading at Rs 486 per share, which was 2.34 percent higher than the previous closing price of Rs 474.9.
Akums Drugs & Pharmaceuticals Ltd is a leading Indian contract manufacturer of pharmaceutical products. The company specializes in producing a wide range of generic drugs, including formulations for tablets, capsules, and injectables. Akums serves both domestic and international markets, with a strong presence in over 50 countries.
2. Wockhardt Ltd
The shares of Wockhardt Ltd, with a total market capitalization of Rs 24,555.45 Crore on Thursday, hit a 5 percent upper circuit at Rs 1,511.3 per share in the morning session today.
Wockhardt Ltd is a global pharmaceutical and biotechnology company headquartered in India. It specializes in developing, manufacturing, and marketing a wide range of generic drugs, vaccines, and biotechnology products. With a strong presence in over 20 countries, Wockhardt focuses on sectors like healthcare, animal health, and active pharmaceutical ingredients (APIs).
Also read: Chemical stock with 50% EBITDA growth guidance for FY25 to add to your watchlist
3. Aurobindo Pharma Ltd
The shares of Aurobindo Pharma Ltd, with a total market capitalization of Rs 70,480.28 Crore on Thursday, were trading at Rs 1,213 per share, which was 4.7 percent higher than the previous closing price of Rs 1,158.6.
Aurobindo Pharma Ltd is a leading global pharmaceutical company based in India, known for producing generic medicines and active pharmaceutical ingredients (APIs). It offers a wide range of products across therapeutic areas like antibiotics, antiretrovirals, and oncology. Aurobindo has a strong presence in over 150 countries, including the U.S., Europe, and Asia.
4. Torrent Pharmaceuticals Ltd
The shares of Torrent Pharmaceuticals Ltd, with a total market capitalization of Rs 1.10 Lakh Crore on Thursday, were trading at Rs 3,265.7 per share, which was 1.8 percent higher than the previous closing price of Rs 3,207.
Torrent Pharmaceuticals Ltd is a prominent Indian pharmaceutical company that specializes in generic drugs and active pharmaceutical ingredients (APIs). It offers a wide range of products across therapeutic areas such as cardiology, neurology, and gastrointestinal disorders. With a strong international presence, Torrent Pharma operates in over 40 countries, including the U.S. and Europe.
5. Cipla Ltd
The shares of Cipla Ltd, with a total market capitalization of Rs 1.20 Lakh Crore on Thursday, were trading at Rs 1,488 per share, which was 2.5 percent higher than the previous closing price of Rs 1,452.3.
Cipla Ltd is a leading global pharmaceutical company known for its wide range of generic medicines and active pharmaceutical ingredients (APIs). It specializes in therapeutic areas such as respiratory, cardiology, oncology, and anti-retroviral drugs. Cipla has a strong international presence, operating in over 150 countries.
Written By Adhvaitha Nayani
Disclaimer
The views and investment tips expressed by investment experts/broking houses/rating agencies on tradebrains.in are their own, and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Dailyraven Technologies or the author are not liable for any losses caused as a result of the decision based on this article. Please consult your investment advisor before investing.
